Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT01264692

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
Idorsia Pharmaceuticals Ltd. (from the registry)
Registry
  • NCT NCT01264692
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Israel, Serbia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01264692. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Essential Hypertension
Acronym
REDUCE-1
Condition
Essential Hypertension
Intervention (Drug)
ACT-280778
Intervention (Drug)
Placebo
Intervention (Drug)
Amlodipine
Lead sponsor
Idorsia Pharmaceuticals Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01264692
Content hash
ac446b4fc8c45e862d2c49926044457bb6a7f866f4dc285445d2582dea920f6d